PharmAbcine Advances PMC-403 in Phase 1 Trials for nAMD Treatment

PharmAbcine, Inc, a clinical-stage firm developing next generation therapeutics to treat medical needs, declared the decision to accelerate PMC-403, its candidate treatment for neovascular age-related macular degeneration (nAMD), to the fourth single-dose group of 4mg and first multiple-dose group of 3mg in Phase 1 clinical trial.

A novel TIE2-activating antibody known as PMC-403 works by stabilizing blood vessels that are diseased or leaky. TIE2 receptors, communicated on endothelial cells, are engaged with vessel standardization cycles like angiogenesis and intercellular adhesion.

This Stage 1 clinical trial targets patients with neovascular age-related macular degeneration who are no longer responding to anti-VEGF standard therapeutics. As a result of the SRC's decision, the trial will move on to the highest single dose cohort (four milligrams) and the first multiple ascending dose cohort (three milligrams), which could provide additional data from the Phase 1 study.

Dr. Weon Sup Lee, Head of R&D and Chief Technology Officer at PharmAbcine, stated, "Despite standard anti-VEGF treatments, many patients with neovascular age-related macular degeneration continue to experience vision loss and retinal vascular leakage. We are committed to delivering an innovative new drug with differentiated mode of action for these patients." He added, "If final safety is confirmed in this Phase 1 trial, the likelihood of advancing to Phase 2 will increase, paving the way for the commercialization of this treatment."